

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-88 (Canceled)

89. (Currently amended) A method for determining the risk of tumor recurrence or spread in a patient suffering from prostate cancer, said method comprising:

(a) determining a cytosolic BAG-1 protein ~~gene expression~~ level in a cancerous prostate tissue sample from said patient, ~~wherein said BAG-1 gene expression level is determined by measuring cytosolic BAG-1 protein;~~ and

(b) comparing said cytosolic BAG-1 protein ~~gene expression~~ level in said sample patient to a reference cytosolic BAG-1 protein ~~gene expression~~ level, said reference ~~BAG-1 gene expression~~ level being a level of cytosolic BAG-1 protein ~~gene expression~~ above which correlates with an increased risk of tumor recurrence or spread and below which correlates with a decreased risk of tumor recurrence or spread, thereby determining the risk of tumor recurrence or spread in said patient.

90. (Previously presented) The method of claim 89, wherein said tumor spread comprises tumor metastasis.

91. (Canceled)

92. (Currently amended) The method of claim 89, wherein said cytosolic BAG-1 protein level is determined with an antibody specific for BAG-1 protein.

93. (Canceled)

94. (Canceled)

95. (Currently amended) The method of claim 89, wherein said cytosolic BAG-1 ~~gene encodes a protein~~ is selected from the group consisting of BAG-1, BAG-1N[[,]] and BAG-1M and BAG-1L.

96. (Currently amended) The method of claim 89, wherein said cytosolic BAG-1 protein gene-expression level is determined using an immunoassay.

97. (Previously presented) The method of claim 96, wherein said immunoassay is an immuno-polymerase chain reaction (immuno-PCR) assay.

98. (Currently amended) The method of claim 89, wherein said reference cytosolic BAG-1 protein gene-expression level is a level of cytosolic BAG-1 protein gene-expression above which correlates with increased risk of tumor recurrence or spread in a first group of patients compared to a second group of patients, said second group of patients having cytosolic BAG-1 protein gene-expression levels below said reference level.

99. (Currently amended) A method for determining a prognosis of survival in a patient suffering from prostate cancer, said method comprising:

(a) determining a cytosolic BAG-1 protein gene-expression level in a cancerous prostate tissue sample from said patient, ~~wherein said BAG-1 gene-expression level is determined by measuring cytosolic BAG-1 protein;~~ and

(b) comparing said cytosolic BAG-1 protein gene-expression level in said sample patient to a reference cytosolic BAG-1 protein gene-expression level, said reference BAG-1 gene-expression level being a level of cytosolic BAG-1 protein gene-expression above which correlates with decreased survival and below which correlates with increased survival, thereby determining a prognosis of survival in said patient.

100. (Previously presented) The method of claim 99, wherein said survival is overall survival.

101. (Previously presented) The method of claim 99, wherein said survival is distant metastasis-free survival.

102. (Canceled)

103. (Currently amended) The method of claim 99 [[102]], wherein said cytosolic BAG-1 protein level is determined with an antibody specific for BAG-1 protein.

104. (Canceled)

105. (Canceled)

106. (Currently amended) The method of claim 99, wherein said cytosolic BAG-1 ~~gene encodes~~ a protein is selected from the group consisting of BAG-1, BAG-1N[[,]] and BAG-1M and BAG-1L.

107. (Currently amended) The method of claim 99, wherein said cytosolic BAG-1 protein gene-expression level is determined using an immunoassay.

108. (Previously presented) The method of claim 107, wherein said immunoassay is an immuno-polymerase chain reaction (immuno-PCR) assay.

109. (Currently amended) The method of claim 99, wherein said reference cytosolic BAG-1 protein gene-expression level is a level of cytosolic BAG-1 protein gene-expression above which correlates with decreased survival in a first group of patients compared to a second group of patients, said second group of patients having cytosolic BAG-1 protein gene-expression levels below said reference level.

110. (Canceled)

111. (Withdrawn) The method of claim 95, wherein said BAG-1 gene encodes BAG-1N.

112. (Withdrawn) The method of claim 95, wherein said BAG-1 gene encodes BAG-1M.

113. (Canceled)

114. (Canceled)

115. (Withdrawn) The method of claim 106, wherein said BAG-1 gene encodes BAG-1N.

117. (Withdrawn) The method of claim 106, wherein said BAG-1 gene encodes BAG-1L.